Eli Lilly Past Earnings Performance
Past criteria checks 1/6
Eli Lilly has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 8.8% per year. Eli Lilly's return on equity is 48.2%, and it has net margins of 15.4%.
Key information
8.3%
Earnings growth rate
9.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 8.8% |
Return on equity | 48.2% |
Net Margin | 15.4% |
Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
Apr 22Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Eli Lilly: The Party Is Not Over
Mar 23Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Mar 17Eli Lilly: Yes, It Is Too Late To Join The Party
Feb 20Eli Lilly: Overvaluation Is A Big Red Flag
Feb 14Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)
Feb 07Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
Jan 31Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30
Jan 24Eli Lilly: The Cupboard Is Fully Stocked
Jan 19Eli Lilly: The Buzz Is Not Over
Jan 11Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30
Jan 10Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year
Dec 27Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now
Dec 24Eli Lilly: Long Path To A Trillion
Dec 21Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
Nov 30Eli Lilly: Perfectly Priced Healthcare Giant
Nov 16Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?
Nov 09Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Oct 30Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
Oct 11Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
Oct 05Eli Lilly: Don't Be Fooled By Greed
Sep 20Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?
Sep 11Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching
Sep 11Is Eli Lilly (NYSE:LLY) Using Too Much Debt?
Aug 24Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
Aug 23Eli Lilly Q2: Dividends Don't Lie
Aug 14Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro
Aug 08Revenue & Expenses BreakdownBeta
How Eli Lilly makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 34,124 | 5,240 | 6,941 | 9,313 |
30 Sep 23 | 32,073 | 4,988 | 6,682 | 8,747 |
30 Jun 23 | 29,516 | 6,498 | 6,515 | 8,140 |
31 Mar 23 | 27,691 | 5,687 | 6,236 | 7,566 |
31 Dec 22 | 28,541 | 6,245 | 6,068 | 7,191 |
30 Sep 22 | 29,240 | 6,033 | 6,037 | 7,093 |
30 Jun 22 | 29,071 | 5,692 | 6,020 | 6,996 |
31 Mar 22 | 29,323 | 6,129 | 6,104 | 6,869 |
31 Dec 21 | 28,318 | 5,582 | 6,142 | 6,931 |
30 Sep 21 | 27,759 | 5,972 | 6,119 | 6,870 |
30 Jun 21 | 26,726 | 6,071 | 6,069 | 6,631 |
31 Mar 21 | 25,486 | 6,093 | 5,867 | 6,366 |
31 Dec 20 | 24,540 | 6,194 | 5,869 | 5,976 |
30 Sep 20 | 23,214 | 5,573 | 6,019 | 5,829 |
30 Jun 20 | 22,950 | 5,618 | 5,924 | 5,745 |
31 Mar 20 | 23,087 | 5,533 | 6,048 | 5,757 |
31 Dec 19 | 22,320 | 4,638 | 6,004 | 5,595 |
30 Sep 19 | 21,843 | 4,264 | 5,984 | 5,405 |
30 Jun 19 | 21,673 | 4,103 | 6,019 | 5,305 |
31 Mar 19 | 21,622 | 2,545 | 5,913 | 5,174 |
31 Dec 18 | 21,493 | 3,151 | 5,735 | 5,051 |
30 Sep 18 | 22,016 | 372 | 5,855 | 5,146 |
30 Jun 18 | 22,368 | -166 | 5,975 | 5,205 |
31 Mar 18 | 22,607 | 1,074 | 6,210 | 5,207 |
31 Dec 17 | 19,974 | -86 | 5,733 | 5,096 |
30 Sep 17 | 22,471 | 2,225 | 6,475 | 5,321 |
30 Jun 17 | 22,005 | 2,447 | 6,526 | 5,217 |
31 Mar 17 | 21,585 | 2,187 | 6,483 | 5,281 |
31 Dec 16 | 21,222 | 2,738 | 6,330 | 5,310 |
30 Sep 16 | 20,837 | 2,444 | 6,460 | 5,238 |
30 Jun 16 | 20,605 | 2,466 | 6,471 | 5,145 |
31 Mar 16 | 20,179 | 2,319 | 6,483 | 4,978 |
31 Dec 15 | 19,959 | 2,408 | 6,533 | 4,796 |
30 Sep 15 | 19,704 | 2,359 | 6,535 | 4,538 |
30 Jun 15 | 19,620 | 2,059 | 6,631 | 4,638 |
31 Mar 15 | 19,577 | 2,192 | 6,659 | 4,664 |
31 Dec 14 | 19,616 | 2,391 | 6,621 | 4,734 |
30 Sep 14 | 20,303 | 2,690 | 6,775 | 5,023 |
30 Jun 14 | 21,200 | 3,392 | 6,755 | 5,158 |
31 Mar 14 | 22,194 | 3,865 | 6,959 | 5,293 |
31 Dec 13 | 23,113 | 4,685 | 7,126 | 5,531 |
30 Sep 13 | 23,262 | 4,785 | 7,150 | 5,519 |
30 Jun 13 | 22,932 | 4,908 | 7,255 | 5,484 |
Quality Earnings: LLY has a high level of non-cash earnings.
Growing Profit Margin: LLY's current net profit margins (15.4%) are lower than last year (21.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LLY's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: LLY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LLY had negative earnings growth (-16.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13.2%).
Return on Equity
High ROE: Whilst LLY's Return on Equity (48.24%) is outstanding, this metric is skewed due to their high level of debt.